Med. praxi. 2017;14(1):25-27 | DOI: 10.36290/med.2017.006

Is it any real cause of safety concern regarding high-dose statin treatment?

doc. MUDr. Otto Mayer, CSc.
II. interní klinika UK LF a FN Plzeň

Statin treatment represents one of most important procedure in secondary prevention of atherovascular disease or in primary

prevention of asymptomatic high-risk subjects. However, the prescription rate of high-dose statin remains in clinical reality far

from being optimal, and possible reason can be safety concerns. The article summarizes recent facts on the risk of statin-induced

myotoxicity, as the most prominent adverse effect of this treatment.

Keywords: statin, treatment safety, myotoxicity, dosage

Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayer O. Is it any real cause of safety concern regarding high-dose statin treatment? Med. praxi. 2017;14(1):25-27. doi: 10.36290/med.2017.006.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur Heart J 2012; 33: 1635-1701. Go to original source...
    2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet 2005; 366: 1267-1278. Go to original source... Go to PubMed...
    3. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy, J Am Coll Cardiol 2006; 48: 438-445. Go to original source... Go to PubMed...
    4. Mayer Jr. O, Bruthans J. In what extend we can reach the current LDL-cholesterol treatment goals in secondary prevention, Vnitr Lek 2015; 61: 439-446. Go to PubMed...
    5. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market, Curr Control Trials Cardiovasc Med 2001; 2: 205-207. Go to original source... Go to PubMed...
    6. Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis, Am J Med 2006; 119: 400-409. Go to original source... Go to PubMed...
    7. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet 2010; 376: 1670-1681. Go to original source... Go to PubMed...
    8. Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials and clinical experience, JAMA 2015; 313: 1011-1012. Go to original source... Go to PubMed...
    9. Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients, Am J Cardiol 2003; 92: 670-676. Go to original source... Go to PubMed...
    10. Hey-Hadavi JH, Kuntze E, Luo D, et al. Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials, Am J Geriatr Pharmacother, 2006; 4: 112-122. Go to original source... Go to PubMed...
    11. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study, Ann Intern Med 2013; 158: 526-534. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.